Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06329687 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating the Safety of the Nasal Pump
A Phase 4 study, sponsored by Oyster Point Pharma.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT06329687: Clinical Trial Phase 4 study, sponsored by Oyster Point Pharma.
NCT06329687 is a Phase 4 study that was terminated before completion, run by Oyster Point Pharma. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06329687, a Phase 4 study, was terminated before completion, sponsored by Oyster Point Pharma.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The objective of this study is to determine the safety of the Tyrvaya nasal pump.
Primary Outcome
Number of Participants with Adverse Events with the nasal pump with additional silicone lubricant
Interventions
- DRUG Tyrvaya Nasal Pump
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-02-21 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 4 |
Why NCT06329687 stopped before completion
NCT06329687 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Tyrvaya Nasal Pump is the first listed.
NCT06329687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06329687 about?
NCT06329687 is a clinical study titled "A Study Evaluating the Safety of the Nasal Pump". The objective of this study is to determine the safety of the Tyrvaya nasal pump.
What is the current status of trial NCT06329687?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2024-02-21. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT06329687?
The interventions under investigation include: Tyrvaya Nasal Pump (DRUG).
Who is sponsoring clinical trial NCT06329687?
This trial is sponsored by Oyster Point Pharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06329687's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI